GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) saw a large decline in short interest in July. As of July 15th, there was short interest totalling 261,500 shares, a decline of 79.2% from the June 30th total of 1,260,000 shares. Based on an average trading volume of 2,970,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.3% of the company’s stock are short sold.
GeoVax Labs Trading Up 1.6 %
Shares of NASDAQ GOVX traded up $0.04 during trading hours on Friday, hitting $2.62. The stock had a trading volume of 264,185 shares, compared to its average volume of 1,373,865. The firm’s 50-day moving average price is $2.25 and its two-hundred day moving average price is $2.43. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $9.75.
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. On average, research analysts predict that GeoVax Labs will post -7.41 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Roth Capital raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday. Roth Mkm started coverage on GeoVax Labs in a research note on Tuesday, July 16th. They issued a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Tuesday, July 2nd.
View Our Latest Analysis on GOVX
GeoVax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
Further Reading
- Five stocks we like better than GeoVax Labs
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Are Growth Stocks and Investing in Them
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.